A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
University Health Network, Toronto
Actuate Therapeutics Inc.
OHSU Knight Cancer Institute
H. Lee Moffitt Cancer Center and Research Institute
University of California, San Francisco